Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, July 31st.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.12). Vanda Pharmaceuticals had a negative net margin of 2.75% and a negative return on equity of 0.90%. The company had revenue of $47.46 million for the quarter, compared to analysts’ expectations of $48.50 million.

Vanda Pharmaceuticals Stock Up 0.5 %

VNDA opened at $6.18 on Friday. The firm has a 50 day moving average price of $5.72 and a 200-day moving average price of $4.78. Vanda Pharmaceuticals has a twelve month low of $3.30 and a twelve month high of $6.75. The stock has a market capitalization of $359.66 million, a price-to-earnings ratio of -77.25 and a beta of 0.75.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on VNDA shares. Cantor Fitzgerald started coverage on shares of Vanda Pharmaceuticals in a report on Thursday, July 11th. They set an “overweight” rating and a $11.00 price objective for the company. StockNews.com started coverage on shares of Vanda Pharmaceuticals in a report on Saturday, July 20th. They set a “hold” rating for the company.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.